Technologies

time icon April 2, 2015

A class of small-molecule therapeutics for hypertension and inflammatory diseases

Technology description

Summary



Epoxyeicosatrienoic acids (EETs) are lipid metabolites that regulate blood pressure and inflammation. EETs are metabolized by soluble epoxide hydrolase (sEH); therefore, inhibition of sEH may treat hypertension and other medical conditions caused by irregularities in blood pressure, vasodilation, endothelial cell function, and inflammation. However, treatments for these conditions, based on this strategy, do not currently exist because the best-known inhibitors of sEH have poor bioavailability. This technology is a class of potent sEH inhibitors with improved biocompatibility. These inhibitors may potentially be used to treat hypertension, metabolic syndrome, atherosclerosis, erectile dysfunction, stroke, diabetes, and aging in humans. Additionally, these inhibitors may be used to treat laminitis disease in horses.


Non-urea-based sEH inhibitors preserve functionality of lipids that regulate blood pressure and inflammation


The most potent sEH inhibitors are urea-based and are readily metabolized in vivo, limiting their use as pharmaceuticals. The inhibitors described by this technology are based on a stronger and less metabolically active chemical functionality, and are thus more attractive drug candidates. These small molecules are potent inhibitors of sEH in low nanomolar concentrations (IC50's < 2 nM).


Studies investigating the pharmacokinetic profile of these molecules are currently underway.





Tech Ventures Reference: IR 2436

Publications



  • Pecic S, Pakhomova S, Newcomer ME, Morisseau C, Hammock BD, Zhu Z, Rinderspacher A, Deng SX. "Synthesis and structure-activity relationship of piperidine-derived non-urea soluble epoxide hydrolase inhibitors." Bioorg Med Chem Lett. 2013 Jan 15;23(2):417-21.


  • Pecic S, Deng SX, Morisseau C, Hammock BD, Landry DW. "Design, synthesis and evaluation of non-urea inhibitors of soluble epoxide hydrolase." Bioorg Med Chem Lett. 2012 Jan 1;22(1):601-5.


  • Xie Y, Liu Y, Gong G, Smith DH, Yan F, Rinderspacher A, Feng Y, Zhu Z, Li X, Deng SX, Branden L, Vidovic D, Chung C, Schuerer S, Morisseau C, Hammock BD, Landry DW. "Discovery of potent non-urea inhibitors of soluble epoxide hydrolase." Bioorg Med Chem Lett. 2009 Apr 15;19(8):2354-9.


Application area


  • Treatment for hypertension

  • Treatment for inflammation

  • Treatment for metabolic syndrome and syndrome X

  • Treatment for erectile dysfunction

  • Treatment for atherosclerosis

  • Treatment for stroke

  • Preventative treatment for stroke and diabetes

  • Potential anti-aging treatment

  • Advantages


    • Novel approach to treatment of hypertension

    • No treatments for metabolic syndrome currently exist

    • Improved bioavailability and potentially improved pharmacokinetic profile

    由于技术保密工作限制,技术信息无法完全展现,请通过邮箱或短信联系我们,获取更多技术资料。

    More information

    Institution
    Categories
    • Cardiology
    • Diagnosis and treatment
    Keywords:

    summary epoxyeicosatrienoic acids

    soluble epoxide hydrolase

    endothelial cell function

    attractive drug candidates

    low nanomolar concentrations

    下载 PDF 文档


    感兴趣

    Contact us

    知繁业茂-yintrust logo知繁业茂-Branchly Innovation logo 知繁业茂-autmasia logo迈科技 logo